Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Generation Bio Co. (GBIO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.00-0.02 (-0.28%)
At close: 04:00PM EDT
7.35 +0.35 (+5.00%)
After hours: 06:41PM EDT
Advertisement

Generation Bio Co.

301 Binney Street
Cambridge, MA 02142
United States
617 655 7500
https://generationbio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees150

Key Executives

NameTitlePayExercisedYear Born
Dr. Cameron Geoffrey McDonough M.D.Pres, CEO, Sec. & Director935.37kN/A1970
Dr. Matthew Norkunas M.B.A., M.D.Chief Financial Officer604.16kN/A1978
Dr. Matthew Stanton Ph.D.Chief Scientific Officer647.42k2.36M1973
Dr. Douglas Kerr M.B.A., M.D., Ph.D.Chief Medical Officer651.64k1.31M1967
Dr. Tracy Zimmermann Ph.D.Chief Devel. Officer590.56k492.45k1970
Dr. Mark D. Angelino Ph.D.Co-FounderN/AN/A1973
Dr. Robert Kotin Ph.D.Co-Founder & AdvisorN/AN/A1956
Ms. Antionette Paone M.B.A., M.S.Chief Operating OfficerN/AN/A1978
Dr. Jennifer Elliott Esq., J.D., Ph.D.Chief Legal OfficerN/AN/AN/A
Mr. Phillip Samayoa Ph.D.Sr. VP & Head of Corp. Devel.N/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Generation Bio Co.’s ISS Governance QualityScore as of June 1, 2022 is 9. The pillar scores are Audit: 8; Board: 10; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement